Associated Papers
Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.
Oehler VG et al.
Leukemia, 2026
Advances in Targeting BCR-ABLT315I Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules.
Tuzikiewicz A et al.
Molecules (basel, Switzerland), 2026
Comprehensive resistance profiling of chronic myeloid leukaemia associated ABL1 variants against five tyrosine kinase inhibitors using prime editing.
Jung Y et al.
Nature Biomedical Engineering, 2025
Innovative rapid screening for complex BCR-ABL1 kinase domain mutations in TKI-treated leukaemia patients.
Lan Y et al.
British Journal of Cancer, 2025
Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia.
Krizkova J et al.
Leukemia, 2025
Inotuzumab therapy resulted in molecular remission of relapsed/resistant B-cell acute lymphoblastic leukemia with BCR::ABL1 Lys404Glu mutation.
Lewandowski K et al.
Annals of Hematology, 2025
From Sanger to Oxford Nanopore MinION Technology: The Impact of Third-Generation Sequencing on Genetic Hematological Diagnosis.
Larráyoz MJ et al.
Cancers, 2025
Allele-Specific PCR for Detection of Missense Mutations in the Chimeric BCR::ABL1 Gene Causing Failure of Tyrosine Kinase Inhibitor Therapy in CML Patients.
Skripkina A et al.
International Journal of Molecular Sciences, 2025
Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A Report From the RESIDIAG Study.
Guerineau H et al.
American Journal of Hematology, 2025
Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient.
Cullot G et al.
Annals of Hematology, 2025
Characteristics of BCR::ABL1 kinase domain mutations in Vietnamese chronic myeloid leukemia patients.
Dung PC et al.
Leukemia Research Reports, 2025
BCR::ABL1 kinase domain mutations and their predictive value for treatment outcomes in patients with chronic myeloid leukemia treated with first-line imatinib in a low-income setting: Experience from Côte d'Ivoire.
Koffi KG et al.
Leukemia Research Reports, 2025
Quantitative detection of T315I mutations of BCR::ABL1 using digital droplet polymerase chain reaction.
Mu H et al.
Hematology, Transfusion and Cell Therapy, 2024
A Novel Next-Generation Sequencing Assay for the Identification of BCR::ABL1 Transcript Type and Accurate and Sensitive Detection of TKI-Resistant Mutations.
Yan Z et al.
The Journal of Applied Laboratory Medicine, 2024
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.
Innes AJ et al.
Leukemia, 2024
New ABL1 Kinase Domain Mutations in BCR::ABL1-Positive Acute Lymphoblastic Leukemia.
Li Z et al.
Cancer Medicine, 2024
A Retrospective Analysis of BCR-ABL-1 Kinase Domain Mutations in Frontline TKI Resistant Chronic Myeloid Leukemia Patients: A Single Centre Experience.
Datta G et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion, 2024
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.
Leyte-Vidal A et al.
Blood, 2024
Validation of a novel NGS based BCR::ABL1 kinase domain mutation detection assay in Indian cohort.
Chaudhary P et al.
Scientific Reports, 2024
Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.
Seman ZA et al.
Bmc Research Notes, 2024
Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
Benesova A et al.
American Journal of Hematology, 2024
A Retrospective Analysis of BCR-ABL1 Kinase Domain Mutations in the Frontline Drug Intolerant or Resistant Chronic Myeloid Leukemia Patients: An Indian Experience from a High-End Referral Laboratory.
Majumdar A et al.
South Asian Journal of Cancer, 2024
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.
Han HJ et al.
Leukemia, 2024
A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia.
Kato K et al.
International Journal of Hematology, 2024
Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph-positive leukemias.
Sponseiler I et al.
American Journal of Hematology, 2024
BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India.
S A et al.
Leukemia Research Reports, 2024
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
Kockerols C et al.
European Journal of Haematology, 2023
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation.
Nicolini FE et al.
Cancers, 2023
Unraveling the Mystery: Next Generation Sequencing Sheds Light on Neuroblastoma Pathogenesis and Targeted Therapies.
Aktas T et al.
Frontiers in Bioscience (landmark Edition), 2023
Chronic myeloid leukemia kinase domain mutations: A retrospective descriptive study on the therapeutic and prognostic significance in patients at King Edward VIII Hospital, KwaZulu-Natal, South Africa.
Benjamin C et al.
Health Science Reports, 2023
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sánchez R et al.
Scientific Reports, 2022
P-Loop mutations-Negative prognosticators in tyrosine kinase inhibitors resistant chronic myeloid leukemia patients.
Kaleem B et al.
International Journal of Laboratory Hematology, 2022
Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia.
Baer C et al.
Haematologica, 2022
Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening.
Schaal W et al.
Cancer Informatics, 2022
Differences in Variants in the Structural Domain of BCR-ABL1 Kinase between Chinese Han and Minority Patients with Chronic Myeloid Leukemia by Sanger Sequencing and Next-Generation Sequencing.
Abulaiti D et al.
Cytogenetic and Genome Research, 2022
Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing.
Easwar A et al.
Life (basel, Switzerland), 2021
Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells.
Polivkova V et al.
Leukemia, 2021
Diagnostic Validation of a Clinical Laboratory-Oriented Targeted RNA Sequencing System for Detecting Gene Fusions in Hematologic Malignancies.
Lim HJ et al.
The Journal of Molecular Diagnostics : Jmd, 2021
In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy.
Heatley SL et al.
Leukemia & Lymphoma, 2021
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Soverini S et al.
British Journal of Haematology, 2021
ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors.
Shojaei M et al.
Laboratory Medicine, 2021
Influence of genetic polymorphisms in glutathione-S-transferases gene in response to imatinib among Brazilian patients with chronic myeloid leukemia.
Delmond KA et al.
Molecular Biology Reports, 2021
Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining.
Curik N et al.
Frontiers in Oncology, 2021